Novo, GlaxoSmithKline, Pfizer, AbbVie, ShangPharma and Schrödinger are all in line for exits following the small-molecule drug developer's decision to file for an $86.3m initial public offering.

Morphic Therapeutic, a US-based biotechnology developer backed by corporates AbbVie, GlaxoSmithKline, Novo, Pfizer, Schrödinger and ShangPharma, has filed for an $86.3m initial public offering. Founded in 2015, Morphic is working on small-molecule drugs aimed at integrins: protein receptors that control a wide range of cellular processes. The approach has applications in fibrosis, vascular disorders, autoimmune…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.